Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-12-03

Clinical Trial Update: Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating patient-reported outcomes in vericiguat-treated patients with heart failure with preserved ejection fraction (HFpEF).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vericiguat (vericiguat)

Snippet

Sponsor: Bayer | Conditions: Chronic Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: COMPLETED | Results posted: 2020-12-03